Philip Kantoff

Philip Kantoff at Memorial Sloan Kettering Cancer Center led the IMPACT trial that established sipuleucel-T (Provenge) as the first cancer vaccine approved by the FDA, representing a landmark moment for cancer immunotherapy. His decades of prostate cancer research have encompassed hormonal therapy, chemotherapy, and immunotherapy approaches in advanced disease. He has contributed to understanding the biology of castration-resistant prostate cancer and the tumor immune microenvironment. He was previously at Dana-Farber and has trained generations of prostate cancer researchers.